Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ivantis, Inc.
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
Ivantis markets the Hydrus Microstent for minimally invasive glaucoma surgery, a field Alcon exited three years ago when it pulled its CyPass from the market
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
A proposed change to US Medicare billing that would go into effect 1 January might give one manufacturer an edge over its competitor.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.